Skip to main content

Table 5 Adverse events in the two treatment groups

From: The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma

Adverse event Sorafenib group (n = 48) TACE + sorafenib group (n = 56)
Grade I Grade II Grade III Grade IV Grade I Grade II Grade III Grade IV
Hand-foot skin reactions, n (%) 25 (44.64%) 8 (14.29%) 3 (5.36%) 0 24 (42.86%) 3 (5.36%) 3 (5.36%) 0
Vomiting, n (%) 19 (33.93%) 5 (8.93%) 3 (5.36%) 0 26 (46.43%) 4 (7.14%) 1 (1.79%) 0
Diarrhea, n (%) 21 (37.50%) 4 (7.14%) 2 (3.57%) 0 23 (41.07%) 1 (1.79%) 1 (1.79%) 0
Fatigue, n (%) 10 (17.86%) 2 (3.57%) 0 0 8 (14.29%) 4 (7.14%) 0 0
Hypertension, n (%) 19 (33.93%) 3 (5.36%) 0 0 10 (17.86%) 2 (3.57%) 1 (1.79%) 0
Leucopenia, n (%) 5 (8.93%) 2 (3.57%) 0 0 4 (7.14%) 0 1 (1.79%) 0
Anemia, n (%) 5 (8.93%) 2 (3.57%) 0 0 4 (7.14%) 1 (1.79%) 2 (3.57%) 0
Thrombocytopenia, n (%) 3 (5.36%) 2 (3.57%) 2 (3.57%) 0 3 (5.36%) 4 (7.14%) 1 (1.79%) 0
Alopecia, n (%) 2 (3.57%) 1 (1.79%) 0 0 3 (5.36%) 0 1 (1.79%) 0
Gastrointestinal hemorrhage, n (%) 0 0 4 (7.14%) 0 2 (3.57%) 1 (1.79%) 2 (3.57%) 0
Hepatic encephalopathy, n (%) 2 (1.79%) 1 (1.79%)